Highly active antiretroviral therapy plays a central role in the development of lipodystrophy syndrome, which may affect up to 50% of patients depending on the diagnostic criteria used. Most protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTIs) are involved in body fat changes and associated metabolic disturbances. In contrast, non-NRTIs have not been directly related to the onset of this syndrome. One of the most widely used methods to evaluate body fat changes is dual-energy X-ray absorptiometry (DEXA), which can detect differences in the distribution of body fat in patients with and without lipodystrophy. New information from a randomized open-label clinical trial suggests that efavirenz could have greater potential for causing lipoatrophy than lopinavir1ritonavir. This paper examines the impact of efavirenz on adipose tissue and body fat composition in order to evaluate whether this drug plays a role in the development of lipodystrophy. We have focused on the evidence obtained from comparative randomized clinical trials that use an objective measurement of fat distribution, such as DEXA. We analysed available in vitro data and evidence from non-comparative clinical trials.
Introduction
Lipodystrophy arising from the treatment of HIV-1 infection and its associated metabolic alterations (e.g. dyslipidaemia and insulin resistance) is a multifactorial syndrome. Although highly active antiretroviral therapy (HAART) plays a central role in the development of this syndrome, it is also known that adipose tissue disorders are already present in naive HIV-1-infected patients. The mechanisms underlying the onset of this syndrome may represent a response to independent or interdependent factors, such as long-lasting viral infection, host-related factors, specific drugs or a specific combination of drugs. 1 -9 The first drugs to be associated with lipodystrophy were the protease inhibitors (PIs), 1, 2, 6, 10 and this relationship was later confirmed by in vitro studies. 11 -17 The duration of the therapy with nucleoside reverse transcriptase inhibitors (NRTIs), especially thymidine nucleotides, was subsequently observed to be associated with the onset of lipoatrophy and lactic acidosis, 3, 7, 18, 19 mainly as a consequence of the inhibition of DNA polymerase g in the mitochondria. 20, 21 In contrast, non-NRTIs (NNRTIs) have not been directly related to the onset of lipodystrophy. In fact, these were first used in studies on switching therapy from PIs as a means of reversing or stabilizing PI-induced lipodystrophy. 22 -26 In those studies, the replacement of PIs by NNRTIs, generally after 1 year of follow-up, did not lead to any significant change in body fat (i.e. no improvement or worsening).
In clinical terms, lipodystrophy becomes evident by a loss of fat in the face and limbs that may be accompanied by an accumulation of fat on the trunk and the back of the neck. Incidence varies depending on the diagnostic criteria used, but up to 50% of the patients on HAART may experience this condition. 2 -4,6,7,27,28 Alterations in the distribution of body fat are a serious aesthetic problem that can stigmatize patients. Even if patients have controlled HIV infection, adhere to therapy and lead a normal life, lipodystrophy can make them look ill and potentially identify them as AIDS patients. It is no surprise, therefore, that in patients suffering from morphological changes, adherence to therapy may be compromised, thus leading to treatment failure. 29 Furthermore, metabolic alterations such as dyslipidaemia and insulin resistance can increase the risk of cardiovascular diseases in the long term. 30 -34 Unfortunately, there are no objective criteria or case definitions for lipodystrophy. The evaluation of altered fat distribution by patients or physicians is easy; however, it does not allow for comparisons within the same patient or between different studies, because it is not objective. Yet, clinical research requires an evaluation that is as objective as possible in order to reliably determine the incidence of this condition, identify associated risk factors and evaluate the efficacy of preventive and therapeutic measures. In this sense, several different methods have been used to evaluate patients with lipodystrophy: anthropometric measurements, computed tomography, magnetic resonance imaging, sonography and dual-energy X-ray absorptiometry (DEXA). 2 -4,7,35 -38 This technique analyses regional and whole-body composition and is the most widely used one. It has proved useful in the diagnosis and evaluation of lipodystrophy and can detect differences in the distribution of body fat in patients with and without lipodystrophy. 38 Nevertheless, the results vary according to the manufacturer, site, operator and hardware and software versions used. 39 -43 Therefore, the results of DEXA, especially in multicentre studies involving several operators, must be interpreted with caution. The ideal solution would be a central analysis site with as few operators as possible so that variability in the measurements could be reduced. 42 The recent results of a randomized open-label clinical trial suggest that efavirenz could have greater potential for causing lipoatrophy than lopinavirþritonavir. 44 This outcome is surprising, given that NNRTIs were not traditionally considered to be related to the development of lipodystrophy or at least were perceived as lower risk drugs than PIs. This paper aims to analyse the impact of efavirenz on adipose tissue and body fat composition and to evaluate whether this drug plays a role in the development of lipodystrophy. We searched MEDLINE and Embase for randomized clinical trials including efavirenz as part of the antiretroviral treatment schedule and using DEXA to measure fat distribution, as well as the most recent conference abstracts on HIV infection. We also searched for basic science studies on adipocytes in which efavirenz was used. Both clinical and adipocyte studies were included.
In vitro data
Adipocyte differentiation and metabolism seem to be very sensitive to HIV-1 infection, antiretroviral drugs or both. Historically, PIs were the first drugs associated with lipodystrophy and related metabolic disorders, whereas nucleoside analogues (mainly thymidine analogues) were later linked to the development of lipoatrophy. Several mechanisms have been postulated to explain the effects of PIs. Given that it is difficult to determine the adverse effects of a single drug on adipose tissue in patients taking combined antiretroviral treatment, in vitro models (mainly with mouse cells) have been used to examine the effects of these drugs on adipocyte metabolism and differentiation.
The potential mechanisms of the deleterious effects of PIs on fatty tissue include a negative effect on pre-adipocyte differentiation, impaired adipogenesis, promotion of adipocyte death, increased lipolysis and impairment of insulin signalling events and glucose transport. The inhibitory effects of PIs on adipogenesis have been related to the decreased expression of peroxisome proliferator-activated receptors or CCAAT enhancer-binding proteins (C/EBPa) or to altered expression or intranuclear localization of sterol regulatory element-binding protein (SREBP-1c). 11 -17,45 -54 Nevertheless, the effects of PIs on the physiology of human adipocytes are not the same for all the drugs in this group. In this way, atazanavir does not seem to negatively affect adipocyte lipid synthesis or glucose transport, unlike ritonavir, lopinavir, saquinavir and nelfinavir. 55 Information on the effect of nevirapine and efavirenz on adipocyte metabolism is very scarce. In a study evaluating the effects of nevirapine on brown adipocytes, this drug did not significantly impair cell biology and to some extent promoted adipocyte differentiation. 56 In another study evaluating the effect of switching from indinavir to nevirapine on insulin metabolism and adipocyte apoptosis, only an improvement in the glucose/ insulin ratio was demonstrated. Subcutaneous adipocyte apoptosis continued to occur in lipoatrophic areas, suggesting that this strategy cannot reverse lipoatrophy. 57 To our knowledge, there is only one study on the role of efavirenz in this situation. El Hadri et al. 58 attempted to analyse the effects of efavirenz on adipocyte differentiation and metabolism using an in vitro assay with murine (3T3-F442A) cells and human adipocytes exposed to efavirenz at different concentrations (0-50 mM). When incubated with pre-adipocytes during the differentiation process, efavirenz prevented these cells from accumulating lipids, and at high concentrations (40 -50 mM), it also altered the magnitude of adipocyte differentiation. The latter effect was detectable even at low drug concentrations and did not seem to be related to activation of lipolysis, alteration in cell viability (this phenomenon was reversible upon drug withdrawal) or reduced baseline or insulin-stimulated glucose transport that would result in a decreased substrate availability for fatty acid biosynthesis. Nevertheless, the antilipogenic effect of efavirenz is the result of a dramatic down-regulation in the SREBP-1c expression through decreased mRNA levels and, consequently, the expression of the related mature 68 kDa protein.
Because the mature form of SREBP-1c promotes the lipogenic gene expression, the significant decrease in the levels of the 68 kDa SREBP-1c protein probably contributes to impaired lipogenesis in efavirenz-treated cells. In this experiment, the inhibitory effect of efavirenz on cell triglyceride accumulation could be reversed by providing the cells with free fatty acids and by overexpression of a dominant positive form of SREBP-1c.
As the authors suggested, the effect of efavirenz on adipose tissue could be counteracted by de novo hepatic lipid synthesis. Moreover, although efavirenz can accumulate in the adipose tissue 59 and intracellular concentrations seem to be higher than plasma concentrations, 60 the concentrations used in this experiment were higher than those expected at the therapeutic levels. The average plasma C max in clinical studies ranges from 9.1 to 12.9 mM-levels over 12.7 mM are considered toxic and 3.1 mM is considered the minimum efficacious concentration. 61 -65 Further clinical investigation is warranted in this field to ascertain the medical relevance of these observations and whether efavirenz could also alter lipogenesis in hepatocytes.
Recently, Hammond et al. 66 presented data regarding the effects of efavirenz and lopinavir on adipose tissue in HIV-infected patients initiating the first-line therapy. Biopsy samples were assessed for mitochondrial DNA and tissue histology, as well as for cytokine expression. There was no evidence that the use of efavirenz or lopinavir affected mitochondrial DNA depletion or cytokine expression in the adipose tissue, whereas thymidine analogues were strongly associated with mitochondrial DNA depletion and pathological changes characteristic of clinical lipoatrophy.
In summary, in vitro studies show that both PIs and NNRTIs may have an impact on adipocyte metabolism. Although the evidence is greater for PIs, information on the potential role of NNRTIs remains scarce and needs further evaluation.
Clinical data
Lipoatrophy has mainly been associated with NRTIs, especially thymidine analogues and, more specifically, stavudine. 3, 7, 18, 19, 67, 68 Therefore, several studies have explored the possibility of reversing lipoatrophy by switching from thymidine analogues to thymidine-sparing combinations. Nevertheless, once lipoatrophy is established, the results up to 1-2 years have not been promising and recovery of limb fat has been limited. 69 -76 On the contrary, the good tolerability and ease of use of NNRTIs meant that they were initially explored for reducing the toxicity and complexity of PI-based therapy. 22,77 -80 This, together with their antiviral efficacy, has made the combination of efavirenzþ2 NRTIs one of the preferred combinations for naive patients.
81,82 Unlike NRTIs or PIs, NNRTIs have not been directly related to lipodystrophy (specifically lipoatrophy) in cohort studies or clinical trials. To assess the potential role of efavirenz compared with PIs in the emergence of lipodystrophy, we reviewed comparative and non-comparative published clinical studies in which an objective measure of fat distribution, such as DEXA, was performed.
Non-comparative studies
Body fat has been measured by DEXA in five non-comparative trials in which efavirenz was the anchor drug: ABCDE 83 (stavudineþlamivudineþefavirenz versus abacavirþlamuvudine þefavirenz), Gilead Study 934 84 (tenofovirþemtricitabineþ efavirenz versus zidovudineþlamivudineþefavirenz), ACTG 5125s 85 (simplification to 2 NRTIsþefavirenz versus lopinavirþ efavirenz), Gilead 903 86 (tenofovirþlamivudineþefavirenz versus stavudineþlamivudineþefavirenz) and Sweet 87 (switch from zidovudine/lamivudineþefavirenz to tenofovir/emtricitab ineþefavirenz versus zidovudine/lamivudineþefavirenz) ( Table 1 ). These studies show the expected impact of body fat on the population treated with efavirenz and NRTIs.
83 -86 Three involved naive patients and two involved a simplification strategy. In two of the studies (Gilead 903 and Gilead 934), DEXA was not used at the baseline visit, although body fat changes were measured on two occasions during therapy with an interval of 48 weeks between measurements. The follow-ups were long and, except for one case, there were evaluations at 96 weeks. In two of the studies, a clinical evaluation of lipoatrophy was also carried out.
In general, thymidine-analogue-sparing regimens showed a continuous weight gain up to week 144. In the ABCDE study, the weight gain was 913 g in the abacavir (ABC) arm compared with a loss of 1578 g in the stavudine arm. In ACTG 5125s, the gain was 782 g in the NRTI-sparing arm (a 10% increase on baseline) compared with a loss of 850 g (15%) in the arm including NRTIs with efavirenz. In ACTG 5142s, patients simplified therapy after at least 18 months on successful HAART (median time on antiretroviral therapy in the efavirenzþ2 NRTIs arm was 127 weeks) and the NRTI pairs used in 25 of the 31 patients included thymidine analogues (stavudine 6; zidovudine 19). In Gilead 903 and 934, baseline DEXA was not performed because the design of the body composition substudy was established after the initiation of the main study. However, the results of these studies do not show whether body fat remained stable or not with prolonged antiretroviral therapy. Once again, the tenofovir-containing arms, unlike those containing stavudine or zidovudine, continued to show a significant gain in weight (tenofovir 300 g versus zidovudine 700 g in Gilead 934 and tenofovir 2900 g versus stavudine 600 g in Gilead 903). Furthermore, significant differences were also observed in total limb fat between the groups including stavudine or zidovudine compared with tenofovir at week 96: tenofovir 7.7 kg (n ¼ 144) versus zidovudine 5.5 kg (n ¼ 136) (P , 0.001). There were no significant differences in trunk fat between the groups. Diagnosis of lipodystrophy was based on the physician's evaluation. In Gilead 903, clinical lipodystrophy was included among the adverse effects. In both studies, the incidence of lipodystrophy in the thymidine-analogue-sparing groups was very low: tenofovir 3% versus stavudine 19% at 144 weeks in Gilead 903 (P , 0.001) and abacavir 4.8% versus stavudine 38.3% at 96 weeks in the ABCDE study (P , 0.001).
Data from studies in which efavirenz is used as an anchor drug consistently show that when the backbone is composed of non-thymidine analogues, the long-term incidence of lipodystrophy is very low, with a significant gain in weight that continues at least until week 144. Even in those patients treated with zidovudine/lamivudine for a median of 2.9 years, the change to tenofovir/emtricitabine improves the limb fat by an average of 261 g. The development of clinical lipoatrophy in patients treated with efavirenz, after 2-3 years of therapy, has ranged from 15% to 38% when a thymidine analogue is used and from 3% to 4.8% when abacavir or tenofovir is used. Similarly, limb fat changes have ranged from a loss of 1578 g to a gain of 600 g in thymidine analogue-treated patients compared with a net gain of 300 -2900 g in patients not treated with thymidine analogues.
Comparative studies
Four prospective randomized studies have compared alterations in body fat distribution using DEXA: ACTG 5005s 88 (efavirenz versus nelfinavir versus efavirenzþnelfinavir), BMS-034 89 (efavirenz versus non-boosted atazanavir), M03-613 90 (simplification to lopinavir monotherapy after an induction period of 24 -48 weeks of zidovudine/lamivudineþlopinavir versus zidovudine/ lamivudineþefavirenz) and ACTG 5142 44 (efavirenz versus lopinavir versus efavirenzþlopinavir). In all four, the backbone included thymidine analogues, although in ACTG 5142, 34% of the patients received tenofovir instead of stavudine or zidovudine (in ACTG 5142, allocation of NRTIs was not randomized), and in M03-613, patients assigned to lopinavir monotherapy discontinued zidovudineþlamivudine. All patients underwent a DEXA scan at the baseline visit. This was compared with the follow-up scans at week 48, 96 or 144 ( Table 1 ). The patients were mainly males aged 30 -40. In ACTG 5142, the patients had a lower CD4 count, were older and the number of non-white patients was greater than in the other two studies (64% in ACTG 5142 versus 55% in BMS-034 and 49% in ACTG 5005s). Limb ABC, abacavir; ATV, atazanavir; BL, baseline; BMI, body mass index; CBV, zidovudine/lamivudine; ddI-EC, didanosine enteric coated; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; HAART, highly active antiretroviral therapy; LPV, lopinavir; NFV, nelfinavir; NRTI, nucleoside reverse transcriptase inhibitor; Pbo, placebo; pts, patients; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; TDF, tenofovir; TVD, tenofovir/emtricitabine; VAT, visceral adipose tissue; VL, viral load; ZDV, zidovudine; 3TC, lamivudine. a Those patients with DEXA scan at 48 and 96 weeks. b NRTI pairs allowed were ddI-ECþ3TC, ddI-ECþZDV or ddI-ECþd4T, ZDVþ3TC and d4Tþ3TC. c NRTI selected before randomization. All pairs consisted of 3TC plus one of the following: ZDV or d4T-XR or TDF.
fat at baseline was slightly lower in the ACTG 5005s patients, whereas in the other three studies, it was almost normal. 1, 91 In ACTG 5005s, for the group as a whole, limb fat increased during the first 32 weeks and subsequently declined. Patients who received efavirenz did not show significant changes in limb fat at 144 weeks (an increase of 200 g, 2.4% from baseline; P ¼ 0.90). However, in those patients who received nelfinavircontaining regimens, a weight loss of 1900 g corresponding to 23 .8% from baseline (P ¼ 0.05) was observed. After week 32, there was an additional decrease in limb fat of 28.7% per year in the combined nelfinavir and nelfinavirþefavirenz group when compared with efavirenz alone, after adjusting for the nucleoside backbone (P ¼ 0.03). If those patients who received didanosineþstavudine are excluded and only those who were treated with zidovudineþlamivudine are considered, after week 32, limb fat changed by 2.7% per year with efavirenz and by 27.9% per year for the combined nelfinavir and nelfinavirþ efavirenz group (P ¼ 0.03). Trunk fat increased during the first 32 weeks and was maintained over time. The only group that presented a significant increase in body fat was the efavirenz group: 3500 g (32%) (P ¼ 0.01) versus nelfinavir 300 g (2.7%) (P ¼ 0.4) versus nelfinavirþefavirenz 600 g (6.9%) (P ¼ 0.5). If we focus only on patients receiving zidovudineþlamivudine, after week 32, trunk fat changed by 18.9% per year with efavirenz and by 23.5% per year for the combined nelfinavir and nelfinavirþefavirenz arm (P , 0.0001).
In BMS-034, visceral, subcutaneous (appendicular) and total adipose tissue (VAT, SAT and TAT, respectively) did not change significantly within the efavirenz and atazanavir groups between the baseline and week 48 visit, and there were no differences between the efavirenz and atazanavir arms. As for the SAT to TAT ratio and the VAT to TAT ratio, no significant changes from baseline were observed in either treatment group. Although computed tomography results were comparable for the two treatment arms at baseline, there was a modest but statistically significant increase for the atazanavir group compared with the efavirenz group in VAT (33% versus 23%) and TAT (21% versus 10%). Nevertheless, in this study, the follow-up was only made up to 48 weeks, thus making it impossible to draw longterm conclusions.
In M03-613, a significant improvement in limb fat was observed at 96 weeks in the lopinavir monotherapy arm (18% versus 29%), whereas it was not observed for the trunk fat. Nevertheless, differences were more evident from 24 and 48 weeks onwards, maybe reflecting the effect of zidovudine discontinuation at that point.
ACTG 5142 compared three class-sparing regimens for naive subjects: lopinavir (soft-gel)þefavirenz, lopinavirþ2 NRTIs and efavirenzþ2 NRTIs. NRTIs were selected before randomization and the choice was zidovudine 42%, stavudine-XR 24% or tenofovir 34%. The study differs from previous trials in several ways, for example, the definition of lipoatrophy (not used previously in any clinical trial) or the non-randomized choice of NRTI. The median change from baseline through week 96 in limb fat was significantly different between the groups: lopinavirþefavirenz 18%, lopinavir 9.8% and efavirenz 1.4% (P 0.01 for all pairwise comparisons). However, the median change in the trunk fat did not disclose significant differences in any group: lopinavir 19%, lopinavirþefavirenz 17% and efavirenz 12%. The incidence of lipoatrophy (defined as .20% loss in limb fat) at week 96 was significantly different between the groups: efavirenz 32%, lopinavir 17% and lopinavirþefavirenz 9% (P values for pairwise comparisons: lopinavirþefavirenz versus lopinavir, P ¼ 0.013; lopinavirþefavirenz versus efavirenz, P , 0.001; and lopinavir versus efavirenz, P ¼ 0.007). If we look at the differences in the incidence of lipoatrophy at 96 weeks with regard to the NRTIs used, the highest percentage was observed with the thymidine analogues stavudine (42%) and zidovudine (27%), and the lowest percentage was observed with tenofovir (9%). All pairwise comparisons of NRTIs were significant: zidovudine versus tenofovir, P , 0.001; stavudine versus tenofovir, P , 0.001; and stavudine versus zidovudine, P ¼ 0.038. Similarly, the incidence of lipoatrophy was greater in the efavirenz and lopinavir groups when these were associated with thymidine analogues (stavudine . zidovudine . tenofovir) ( Table 2) . A logistic regression model including a randomized arm and NRTIs was applied to the week 96 lipoatrophy data for the NRTI-containing regimens. For lipoatrophy, this analysis showed an odds ratio (OR) of 2.7 (95% CI: 1.5-4.6) for efavirenz versus lopinavir (P , 0.001), 1.9 (95% CI: 1.1-3.5) for stavudine versus zidovudine (P ¼ 0.029) and 0.24 (95% CI: 0.12 -0.5) for tenofovir versus zidovudine (P , 0.001). There were no interactions analyses to examine whether the effect of each NRTI was significantly different for efavirenz or lopinavir.
The most surprising aspect of these results is the analysis according to the number of subjects who presented a reduction of 20% or more in limb fat (taking this cut-off point as that which defines lipoatrophy). Although there is no objective definition of lipoatrophy, an incidence of 32% at 96 weeks seems to be well above that reported for patients treated with efavirenz, even more if we bear in mind that one-third of these patients received tenofovir. Furthermore, the number of patients with a limb fat loss 20% depended to a large extent on the NRTIs that formed the backbone: 51% with stavudine-XR, 49% with zidovudine and 12% with tenofovir. This behaviour was also observed with lopinavir, although less markedly: 33% for stavudine-XR, 16% for zidovudine and 6% for tenofovir. In this sense, the only regimen with no NRTI presented a significantly lower incidence (only 9%). In ACTG 5142, higher baseline CD4 cell count and lower gain in the body and trunk weight were associated with lipoatrophy and smaller gain in limb fat, independently of the antiretroviral regimen used. Analysing fat change as a continuous variable also found male sex, non-AIDS patient, lower baseline extremity fat and smaller increases in cholesterol and LDL cholesterol to be significantly associated with a smaller gain in limb fat. It seems that several factors other than antiretroviral therapy may be important in the pathogenesis of fat loss. 92 How should these results be interpreted? First, we still need information on the baseline characteristics of the patients (body Table 2 . Patients with .20% fat loss in efavirenz and lopinavir/ ritonavir arms in ACTGs 5142 d4T ZDV TDF Total EFV (n) 51% (44) 40% (63) 12% (67) 32% (171) LPV/r (n) 33% (43) 16% (73) 6% (50) 17% (166) d4T, stavudine; EFV, efavirenz; LPV/r, lopinavir/ritonavir; TDF, tenofovir; ZDV, zidovudine. mass index, weight or dispersion of body mass values) to help us interpret correctly the variations observed. A gain in fat in patients who start with normal values may not be desirable or clinically irrelevant-in this sense, the patients in ACTG 5142 were within the normal range for limb fat values (7.1 kg). 28,91,93, Furthermore, even if the definition of lipoatrophy is objective because it is based on DEXA, it is not validated as a measure of the presence of clinically significant lipoatrophy or even as a predictor of the development of lipoatrophy. In fact, patients with evident lipoatrophy have limb fat levels that are 40 -50% lower than those in healthy patients; 71, 73, 75, 85, 86 those with clinically apparent lipoatrophy have at least 30% limb fat loss regardless of baseline total fat or weight 94 and anthropomorphic changes correlate modestly with DEXA measurements. 89 Even in ACTG 5142, only 30% of the subjects with lipoatrophy as defined by DEXA reported fat loss. 92 Therefore, a cut-off at 20% could be too sensitive in clinical terms. 69 In addition, measurement by DEXA does not distinguish between subcutaneous and intra-abdominal fat. 73, 95 As far as thymidine analogues are concerned, it seems obvious that there is a clear relationship between the inclusion of these drugs in the antiretroviral regimen and a greater incidence of limb fat loss 20%. In fact, this was very low (9%) at 96 weeks in the NRTI-sparing group. Similarly, in ACTG 5125s, those patients whose regimens were simplified to lopinavirþefavirenz showed an average gain of 10% (782 g) in limb fat, despite the fact that they had been on thymidineanalogue-containing HAART for 18 months. What ACTG 5142 did reveal was a greater effect of thymidine analogues in the efavirenz group than in the lopinavir group. The OR of efavirenz versus lopinavir for developing lipoatrophy at 96 weeks was 2.7 (95% CI: 1.5-4.6). Nevertheless, no interaction test was carried out to determine whether the effect of the NRTIs (mainly thymidine analogues) was significantly greater in one group than in the other. What seems obvious is that if efavirenz alone had a potentially important role in the development of lipoatrophy, an impact on body fat would also have been observed in the lopinavirþefavirenz group. The behaviour of efavirenz may have been more neutral with respect to limb fat, in that lopinavir was more likely to be associated with fat gain and NRTIs with fat loss. This effect of greater fat gain in the limbs in the PI-containing regimens than in the PI-sparing regimens has also been observed in other studies. 28 In summary, the results of comparative, randomized clinical trials seem to indicate that therapy with efavirenz leads to a gain in the limb fat in all cases. This gain, although modest (1.4%-9.3%), is higher than that produced by nelfinavir, similar to that of atazanavir and lower than that observed with lopinavir. Trunk fat also increases (3.2-32%), although with no significant differences with the PI comparator. Surprisingly, the incidence of lipodystrophy (defined as .20% loss in limb fat) in the ACTG 5142 trial was significantly higher than that of lopinavir (32% versus 17%) and was severely affected by the accompanying NRTI.
Data for lipid outcome
In general, it seems that the lipid profile worsens when the nucleoside backbone includes a thymidine analogue (more evident with stavudine than with zidovudine) than when it includes tenofovir or abacavir (Table 3) . With tenofovir, in particular, plasma triglyceride levels remained unchanged or experienced minor increases. Cholesterol increased moderately with higher increases in HDL-C than in total cholesterol (TC), suggesting an improvement in the atherogenic profile. When efavirenz was combined with lopinavir or NRTI as the backbone in patients switching therapy, the lipid profile was significantly worse in the lopinavir group. 85 The fact that all patients switched from PI-containing regimens probably contributes to this effect. Increases in triglycerides of over 400 -500 mg/dL were more common with thymidine analogues (14-16% versus 3 -4%) or lopinavir (8% versus 4%) than with the comparator, and the use of lipid-lowering agents was also more frequent with NRTIs (16-17% versus 4 -11%).
As for comparative trials between efavirenz and PIs, comparison with nelfinavir disclosed a slightly better lipid profile for efavirenz with a higher increase in HDL-C leading to a lower TC/HDL-C ratio. When compared with atazanavir (nonboosted), efavirenz showed a neutral lipid profile, with a slight increase in cholesterol levels and a stable atherogenic index (TC/HDL-C), whereas atazanavir improved its lipid figures in comparison with baseline. The figures for lipid outcome in ACTG 5142 were equivalent for efavirenz and lopinavir with regard to TC, HDL-C and non-HDL-C, whereas increases in triglycerides were significantly higher in the lopinavir arm. The worst performing arm was the NRTI-sparing regimen, which showed significant elevations in all the parameters tested.
Efavirenz generally behaves neutrally with respect to lipids (depending to a large extent on the accompanying NRTI), with increases in cholesterol that are usually accompanied by increases in HDL-C; therefore, the atherogenic index remains stable or even improves slightly. Therapy involving lopinavir usually leads to an increase in triglyceride values that is not always accompanied by an increase in cholesterol, whereas NRTI-sparing PI-containing regimens typically produce a much higher deterioration in lipids than that observed with lopinavirþ2 NRTIs. 44,83 -86,89,96 -100 In this sense, the progression of lipids in ACTG 5142 did in fact agree with the information from previous studies, and the greatest increases were detected with the NRTI-sparing regimens, whereas the lopinavir group had a significant increase in triglycerides in comparison with the efavirenz group. Nevertheless, we do not have the necessary number of patients with grades 3 and 4 cholesterol or increased triglyceride levels to enable us to provide a more accurate evaluation of these increases.
In summary, the efavirenz lipid profile seems to be neutral and is substantially affected by the NRTI backbone, the most favourable values being observed with tenofovir and abacavir. When compared with other PIs, efavirenz showed a profile that was very similar to that of nelfinavir (worse for cholesterol) or lopinavir (worse for triglycerides) and slightly worse than that of non-boosted atazanavir.
Conclusions and clinical implications
Lipodystrophy remains a major problem for HIV-infected patients. Aside from the metabolic complications that potentially contribute to increased cardiovascular risk, the change in the body appearance can be very stigmatizing. Therefore, any new data in this field are extremely relevant, as shown by the metabolic substudy of ACTG 5142. 
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ACTG 5142 compared the efficacy of two of the preferred regimens for naive patients, efavirenzþ2 NRTIs and lopinavirþ2 NRTIs, with the NRTI-sparing regimen efavirenzþ lopinavir. This study showed the greater efficacy of efavirenzþ2 NRTIs over lopinavirþ2 NRTIs ( proportion without virological failure at 96 weeks: 76% versus 67%) with no significant differences in the comparison with efavirenzþlopinavir (73%). CD4 lymphocyte recovery was significantly better with lopinavir than with efavirenzþ2 NRTIs (285 versus 241 cells/mm 3 ) and similar to that of lopinavirþefavirenz (268 cells/mm 3 ). In the metabolic substudy, the incidence of lipoatrophy, defined as 20% loss of limb fat, was significantly higher in the efavirenzþ2 NRTIs groups than in the lopinavirþ2 NRTIs and efavirenzþlopinavir groups (32% versus 17% versus 9%).
To date, several studies that measure fat variation using DEXA have revealed that the potential role of efavirenz in the development of lipodystrophy is minimal or non-existent and that it depends on the NRTIs that form the backbone. The same cannot be said for lopinavir because before ACTG 5142 the effect of standard regimens containing NRTIs plus lopinavir on body fat was unknown. Direct comparisons of efavirenz with other third-arm drugs have been made in clinical trials with PIs. Patients treated with efavirenz in these studies gained weight and did not show significant losses of limb fat. The same occurred when the comparator was atazanavir, and only when patients received nelfinavir concomitantly was a significant reduction in limb fat observed. The results of ACTG 5142 are consistent with this: a 1.4% gain in limb fat was detected at week 96 for patients receiving efavirenz.
Even though the incidence of lipodystrophy has been significantly reduced by the avoidance of thymidine analogues and the availability of new antiretrovirals, it continues to be a serious problem for those who suffer from it. Therefore, it is essential to have long-term data on the potential for developing lipodystrophy of the most commonly used combinations and of those that include new drugs. To do this, we must have standardized criteria to objectively evaluate lipodystrophy. These criteria would enable us to compare the results of different studies using the same conditions for all, evaluate the long-term outcome of therapeutic and preventive measures, and even design studies to predict the appearance of morphological alterations associated with HAART. ABC, abacavir; BL, baseline; CBV, zidovudine/lamivudine; d4T, stavudine; EFV, efavirenz; HDL-C, HDL cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C: LDL cholesterol; LPV, lopinavir; pts, patients; TC, total cholesterol; TDF, tenofovir; TG, triglycerides; Tx, treatment; ZDV, zidovudine.
